Nigeria - 2019 - Health

Guidance Document for Submission of Application in the Common Technical Document format - Vaccines for Human Use

Ministry of Health, National Agency for Food and Drug Administration and Control, Nigeria

This guideline is technically and structurally inspired by Health Canada’s guidance document on harmonized requirements for the licensing of vaccines and guidelines for the preparation of an application and the World Health Organization (WHO) working document on vaccine prequalification dossier. This guideline document has been developed in pursuance of the National Agency for Food and Drug Administration and Control (NAFDAC) Act Cap. N1, LFN 2014 and made to provide guidance to applicants on the organization of information to be provided to the agency in seeking marketing authorization for Vaccines for human use. The document applies to all vaccines to be authorized for human use, regardless of where they are manufactured.

Process Flow

Department of Registration and Regulatory Affairs

Office of the Director General NAFDAC

Office of the Permanent Secretary, Ministry of Health

Office of the Minister of State for Health

Office of the minister for health

Compare Versions Please select two versions

Guidance Document for Submission of Application in the Common Technical Document format - Vaccines for Human Use Current Version

January 2022

This guideline is technically and structurally inspired by Health Canada’s guidance document on harmonized requirements for the licensing of vaccines and guidelines for the preparation of an application and the World Health Organization (WHO) working document on vaccine prequalification dossier. This guideline document has been developed in pursuance of the National Agency for Food and Drug Administration and Control (NAFDAC) Act Cap. N1, LFN 2014 and made to provide guidance to applicants on the organization of information to be provided to the agency in seeking marketing authorization for Vaccines for human use. The document applies to all vaccines to be authorized for human use, regardless of where they are manufactured.

Request Expert Analysis

Ask one of our policy analysts to take an in-depth look at this policy and provide you with a written summary. An additional cost may apply. Please let us know what questions you are looking to answer.

Thank you for requesting an expert analysis

A member of our team will review your request and reply back to the email address on file.